AbbVie Stock Price Rises 1.8%, Analysts Weigh In

Shares of pharmaceutical giant AbbVie see modest gains as analysts provide mixed outlook on the stock.

Mar. 30, 2026 at 9:56pm

Got story updates? Submit your updates here. ›

An extreme close-up of a series of gears, levers, and other industrial banking mechanisms in shades of grey, bronze, and chrome, conceptually representing the intricate financial infrastructure and machinery that underlies the healthcare and pharmaceutical sectors.AbbVie's stock price fluctuates as analysts weigh in on the pharmaceutical company's outlook, reflecting the complex financial machinery underlying the healthcare industry.North Chicago Today

Shares of AbbVie Inc. (NYSE:ABBV) rose 1.8% on Monday, trading as high as $213.94 before closing at $213.1170. Trading volume was slightly lower than the average daily volume. Several analysts have weighed in on the stock, with some cutting their price targets while others maintain a buy rating.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio spanning immunology, oncology, neuroscience, and other therapeutic areas. Investor sentiment and analyst views on the stock can provide insight into the company's performance and outlook, which is relevant for shareholders and the broader healthcare sector.

The details

The Goldman Sachs Group reissued a 'neutral' rating on AbbVie shares and set a $223.00 price target. UBS Group cut their target price from $240.00 to $230.00 and maintained a 'neutral' rating. Meanwhile, BMO Capital Markets restated an 'outperform' rating, and Evercore reduced their price objective from $232.00 to $228.00 while keeping an 'outperform' rating.

  • AbbVie's share price was up 1.8% on Monday, March 30, 2026.

The players

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and chronic medical conditions.

The Goldman Sachs Group

A multinational investment bank and financial services company that provided a 'neutral' rating and $223.00 price target on AbbVie shares.

UBS Group

A global financial services firm that cut its price target on AbbVie from $240.00 to $230.00 while maintaining a 'neutral' rating.

BMO Capital Markets

An investment bank that restated an 'outperform' rating on AbbVie shares.

Evercore

An independent investment banking advisory firm that reduced its price objective on AbbVie from $232.00 to $228.00 while keeping an 'outperform' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

While AbbVie's stock saw a modest gain, the mixed analyst views highlight the ongoing uncertainty and challenges facing the pharmaceutical industry. Investors will likely continue to closely monitor the company's performance, pipeline developments, and regulatory environment.